Research Papers

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Publication: Lancet Infectious Diseases

Author(s): Muge Cevik, MD Lindsay C Thompson, MPhil Caryn Upton, MD Valéria Cavalcanti Rolla Mookho Malahleha, MD Blandina Mmbaga, PhD Nosipho Ngubane, MD Zamzurina Abu Bakar, MD Mohammed Rassool, MD Ebrahim Variava, MD Rodney Dawson, MD Suzanne Staples, DPhil Umes

5/2024

Tags: Clinical Development, Clinical Trial Results, Global Pipeline, MDR-TB, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide

Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

Publication: PLOS One

Author(s): A Gupta, S Juneja, V Babawale, N R Majidovich, N Ndjeka, P T M Nguyen, P Nargiza Nusratovna, D R Omanito, T T Pakasi, Y Terleeva, A Toktogonova, Y Waheed, Z Myint, Z Yanlin, S Sahu

1/2024

Tags: Advocacy, Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Policy, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

Publication: International Journal of Tuberculosis and Lung Disease

Author(s): C. D. Tweed, G. H. Wills, A. M. Crook

3/2021

Tags: Clinical Trial Results, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide, STAND/NC-006

Predictive modeling to study the treatment-shortening potential of novel tuberculosis drug regimens, towards bundling of preclinical data

Author(s): Saskia E Mudde, Rami Ayoun Alsoud, Aart van der Meijden, Anna M Upton, Manisha U Lotlikar, Ulrika S H Simonsson, Hannelore I Bax, Jurriaan E M de Steenwinkel

2/2021

Tags: Bedaquiline (TMC-207), Linezolid, Moxifloxacin, Pharmacodynamics, Pharmacokinetics, Preclinical Data, Pretomanid/PA-824, Pyrazinamide, Regimen Change

Phase 1 Study of the Effects of the Investigational Tuberculosis Treatment Pretomanid, Alone and in Combination with Moxifloxacin, on the QTc Interval in Healthy Volunteers

Author(s): Mengchun Li , George A Saviolakis , Wael El-Amin , Mamodikoe K Makhene , Blaire Osborn , Jerry Nedelman , Tian J Yang , Daniel Everitt

12/2020

Tags: Clinical Trial Results, Moxifloxacin, Pretomanid/PA-824

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Publication: The Lancet Respiratory Medicine

Author(s): Conor D Tweed, Rodney Dawson, Divan A Burger, Almari Conradie, Angela M Crook, Carl M Mendel, Francesca Conradie, Andreas H Diacon, Nyanda E Ntinginya, Daniel E Everitt, Frederick Haraka, Mengchun Li, Christo H van Niekerk, Alphonse Okwera

11/2019

Tags: Bedaquiline (TMC-207), BPaZ, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-005, PaMZ, Pretomanid/PA-824, Trial Design

Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations

Publication: BMC Infectious Diseases

Author(s): Emily A. Kendall, Shelly Malhotra, Sarah Cook-Scalise, Claudia M. Denkinger, David W. Dowdy

9/2019

Tags: Bedaquiline (TMC-207), Moxifloxacin, Pretomanid/PA-824, Pyrazinamide, Regimen Change

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton, Mdluli, Fotouhi, Nuermberger EL

4/2019

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Publication: BMC Medicine

Author(s): Tweed C, Mendel, C. Murray, S.,Gillespie, S., Crook, A.,et al.

3/2018

Tags: Moxifloxacin, ReMoxTB

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fl uoroquinolones: results from a multicountry surveillance project

Publication: Zignol, Matteo, Anna Dean, and Natavan Alikhanova. "Population-based Resistance of Mycobacterium Tuberculosis." The Lancet (Published Online July 7, 2016 Http://dx.doi.org/10.1016/S1473-3099(16)30190-6):

7/2016

Tags: Drug-Sensitivity Testing, MDR-TB, Moxifloxacin, Pyrazinamide, TB Burden

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

Publication: Phillips PPJ, Mendel CM, Burger DA, et al. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Medicine. 2016 Mar.14:19. doi: 10.1186/s12916-016-0565-y

3/2016

Tags: Biomarkers, Clinical Development, Moxifloxacin, ReMoxTB, Trial Design

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant...

Publication: Dawson R, Diacon AH, Everitt D, et. al. Efficiency and safety of.... Lancet. 2015 May 2;385(9979):1738-47. doi: 10.1016/S0140-6736(14)62002-X.

5/2015

Tags: Clinical Development, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-002, PaMZ, Pretomanid/PA-824, Pyrazinamide

Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models

Publication: Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15.

4/2015

Tags: Clinical Development, HRZE, Moxifloxacin, Preclinical Data, Preclinical Models, ReMoxTB

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis

Publication: Alffenaar JW, Gumbo T, Aarnoutse R. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 Feb 5;372(6):576. doi: 10.1056/NEJMc1414718#SA1.

2/2015

Tags: Clinical Development, Clinical Trial Results, HRZE, Moxifloxacin, ReMoxTB

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

Publication: New England Journal of Medicine

Author(s): Gillespie, S., Mende, C., Murray, S., et.al

10/2014

Tags: Moxifloxacin

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

Publication: Gillespie SH, Crook AM, McHugh TD, et. al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426.

4/2014

Tags: Clinical Development, Clinical Trial Results, HRZE, Moxifloxacin, ReMoxTB

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen

Publication: Dutta NK, Alsultan A, Gniadek TJ, et. al. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13.

8/2013

Tags: HRZE, Moxifloxacin, PaMZ, Preclinical Data, Pretomanid/PA-824, Pyrazinamide

Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply

Publication: Diacon AH, Donald PR, Mendel CM. Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply. Lancet. 2013 Jan 12;381(9861):112-3. doi: 10.1016/S0140-6736(13)60042-2.

1/2013

Tags: Clinical Development, Editorials, Moxifloxacin, NC-001, PaMZ, Pretomanid/PA-824, Pyrazinamide, Trial Design

In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters

Publication: Upton AM, Cho S, Yang TJ, et. al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. doi: 10.1128/AAC.03823-14.

6/2012

Tags: Clofazamine, Drug Discovery, Moxifloxacin, Preclinical Data

Moxifloxacin for tuberculosis

Publication: Mendel C, Springsklee M. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012 Mar;12(3):176-7; author reply 177-8. doi: 10.1016/S1473-3099(11)70351-6.

3/2012

Tags: Advocacy, Clinical Development, Drug-Sensitivity Testing, Editorials, MDR-TB, Moxifloxacin, Policy, Regimen Change